(Original title: Changchun High-tech 3rd limit down, saying that the impact of centralized procurement has not yet been determined)
Changchun High-tech (000661) fell by the limit for 3 consecutive trading days under the fermentation of centralized procurement news. On the evening of January 23, Changchun High-tech issued an announcement on abnormal fluctuations in stock trading, saying that the centralized procurement of medicines in Guangdong Province has not yet officially started the bidding process, and the specific impact on the company’s performance will also depend on Jinsai Pharmaceutical’s actual participation in bidding and the results of the selection. and the winning price, etc., the impact of this centralized procurement on the company and the degree of impact have not yet been determined.
At the same time, with regard to the stock pledge of the company’s controlling shareholder, Changchun Hi-Tech stated that relevant shareholders will take supplementary guarantee measures such as supplementary property mortgages, supplementary guarantees, and early repayment to ensure that the pledgee will not take measures to liquidate positions.
Centralized procurement has not yet started bidding
On January 19, the Guangdong Provincial Drug Trading Center website announced relevant centralized procurement documents, which covered the growth hormone products of Changchun High-tech subsidiary Jinsai Pharmaceutical. Affected by the news, Changchun Hi-Tech’s stock price fell by the limit on January 19, and continued to drop by the limit on January 20 and 21. The latest stock price was 184.36 yuan per share, and the company’s total market value evaporated by 27.8 billion yuan.
Data from the Dragon Tiger List shows that institutions and hot money have sold off Changchun Hi-Tech in the past three trading days, and the total net sales of institutional seats has exceeded 350 million yuan. On January 20, there were 4 institutions in the top five sellers on the Dragon Tiger list, with a total net sales of over 170 million yuan. As of the close on January 21, there were still 128,000 sell orders at the limit-down price.
Growth hormone categories are divided into water injection and powder injection. Previously, industry insiders predicted that powder injection would be included in this round of centralized procurement, and in this centralized procurement notice, water injection was also included in the scope of centralized procurement. According to market analysis, in this round of centralized procurement, the price reduction of water needles following winning the bid is far greater than that of powder needles. If the price structure changes significantly, Changchun High-tech will be hit to a certain extent.
In response to the abnormal fluctuations in the company’s stock, Changchun High-tech said that it has checked the relevant matters. Recently, investors have paid more attention to the documents related to the centralized procurement of medicines in Guangdong Province. Changchun Hi-Tech stated that the company’s subsidiary Jinsai Pharmaceutical’s recombinant human growth hormone for injection and recombinant human growth hormone injection were included in the scope of centralized procurement. At present, the bidding process has not yet officially started for this centralized procurement of drugs. The specific impact on the company’s performance will also depend on the actual participation of Jinsai Pharmaceutical in the bidding, the results of the selection and the selection price, etc. The impact of this centralized procurement on the company and The extent of the impact has not yet been determined.
Changchun Hi-Tech stated that the company and Jinsai Pharmaceutical will take effective protection of the company’s interests as the starting point, and formulate relevant plans on the premise of not violating laws and regulations. In addition, the company has not found other major events that may have a greater impact on the company’s stock price.
controlling shareholderStock pledge will not close the position
The pledge of Changchun Hi-Tech’s controlling shareholder was also mentioned by investors. On January 20, an investor asked, among the stocks pledged by major shareholders, nearly 30 million shares reached the liquidation line on January 20, will they be liquidated?
In this regard, Changchun Hi-Tech stated on the interactive platform that the pledge of relevant shares by major shareholders is the pledge guarantee provided by the relevant bank loans, which is not completely consistent with the setting of the liquidation line for pledged repurchase transactions. The company will remind shareholders to pay full attention to stock price fluctuations. , to avoid related risks.
“As for the stock pledge of the company’s controlling shareholder, following confirming with the pledger, the company’s indirect controlling shareholder Longxiang Investment Holding Group Co., Ltd., and Changchun New District Development Group Co., Ltd., the relevant shareholders will take supplementary other property mortgages, supplementary guarantees, early repayment, etc. Supplementary security measures to ensure that the pledgee will not take measures to close positions.” In the announcement on the evening of January 23, Changchun High-tech responded once more. Changchun High-tech also said that the state-owned assets supervision department of Changchun New Area will also pay close attention to the relevant situation to avoid risks.
It is worth mentioning that when the stock price fell continuously, Changchun High-tech announced that the executives increased their holdings and other news. On January 21, Changchun Hi-Tech announced that some of the company’s directors, supervisors, and senior managers increased their holdings of the company’s shares through centralized bidding transactions on the Shenzhen Stock Exchange trading system on the same day. A total of 84,700 shares of the company were added that day.
At the same time, Changchun Hi-Tech stated that from December 3, 2021 to January 21, 2022, a total of 2.4732 million shares of the company were repurchased through centralized bidding transactions through the special securities account for repurchase, accounting for 0.61% of the company’s total share capital, of which The highest transaction price was 308.35 yuan per share, the lowest transaction price was 184.36 yuan per share, and the total transaction amount was 600 million yuan (including transaction costs). So far, the company’s repurchase plan has been implemented.
